GeneDx Holdings (WGS) Research & Development (2020 - 2025)
Historic Research & Development for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to $19.8 million.
- GeneDx Holdings' Research & Development rose 6998.71% to $19.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.1 million, marking a year-over-year increase of 2736.19%. This contributed to the annual value of $45.7 million for FY2024, which is 2152.89% down from last year.
- GeneDx Holdings' Research & Development amounted to $19.8 million in Q3 2025, which was up 6998.71% from $15.1 million recorded in Q2 2025.
- GeneDx Holdings' 5-year Research & Development high stood at $53.1 million for Q1 2021, and its period low was $10.9 million during Q2 2024.
- Its 5-year average for Research & Development is $18.0 million, with a median of $14.6 million in 2023.
- Examining YoY changes over the last 5 years, GeneDx Holdings' Research & Development showed a top increase of 12730.92% in 2022 and a maximum decrease of 5988.37% in 2022.
- Over the past 5 years, GeneDx Holdings' Research & Development (Quarter) stood at $22.2 million in 2021, then rose by 9.53% to $24.4 million in 2022, then tumbled by 49.73% to $12.2 million in 2023, then dropped by 5.39% to $11.6 million in 2024, then soared by 71.12% to $19.8 million in 2025.
- Its Research & Development stands at $19.8 million for Q3 2025, versus $15.1 million for Q2 2025 and $12.6 million for Q1 2025.